

DEDiCATES study: Devicedetected Sleep Apnea



Hye Bin Gwag

Cardiology, Sungkyunkwan University School of Medicine, Samsung Changwon Hospital, Korea

Korean Heart Rhythm Society COI Disclosure

Name of First Author: Hye Bin Gwag


This study was supported by Boston Scientifics.




Background

- Sleep-disordered breathing (SBD); sleep apnea
 - Most-common comorbidities in cardiovascular disease patients
 - well-known risk factor for wide range of cardiovascular disease including cardiac arrhythmias
 - up to 50% in CIED patients


- Diagnosis and monitoring of SDB
 - improve quality of life & provide survival benefits
 - Gold standard: polysomnography








- Device function for SDB detection (AP scan)
 - Using a respiratory sensor, impedance-based
 - Measurement of changes in transthoracic impedance during respiration
 - baseline respiratory amplitude and interval (*minute ventilation signal*)









• AP scan

 Apnea/hypopnea events = significantly reduced amplitude (below 74% of baseline) for prolonged duration (>10 s)








Respiratory Disturbance Index (RDI)

= average number of apnea/hypopnea events per hour per night





Relevant studies

- Comparable performance in diagnostic accuracy of SDB to conventional PSG
- Night-to-night variability in SDB severity
- Prognostic value of CIED-detected SDB in risk of AF

- Only pacemaker
- Limited to AF occurrence during maximal 1 year follow-up



Introduction

DEvice-**D**etected **CA**rdiac **T**achyarrhythmic **E**vents and **S**leep-disordered Breathing (**DEDiCATES**) study

• Prospective multicenter observational study; 16 centers in Korea, 2-year follow-up

• Aim: to determine whether device-detected SDB events are associated with increased risk of cardiac arrhythmias or other cardiovascular morbidities






Contents lists available at ScienceDirect

International Journal of Cardiology

journal homepage: www.elsevier.com/locate/ijcard



Rationale, design, and endpoints of the 'DEvice-Detected CArdiac Tachyarrhythmic Events and Sleep-disordered Breathing (DEDiCATES)' study: Prospective multicenter observational study of device-detected tachyarrhythmia and sleep-disordered breathing*



Hye Bin Gwag ^a, Youngjun Park ^a, Seong Soo Lee ^a, June Soo Kim ^a, Kyoung-Min Park ^a, Young Keun On ^a, Dae In Lee ^b, Dong-Gu Shin ^c, Eue-Keun Choi ^d, Gu-Hyun Kang ^e, Hyoung-Seob Park ^f, Hyung Wook Park ^g, Jae-Min Shim ^h, Jae-Sun Uhm ⁱ, Jun Kim ^j, Jun-Hyung Kim ^k, Ki-Woon Kang ^l, Sang Weon Park ^m, Yong-Seog Oh ⁿ, Youngjin Cho ^o, Young Soo Lee ^p, Seung-Jung Park ^{a,*}



DEvice-Detected CArdiac Tachyarrhythmic Events and Sleep-disordered Breathing (DEDiCATES) (DEDiCATES)


ClinicalTrials.gov ID NCT03614377

Sponsor Samsung Medical Center

Information provided by Samsung Medical Center (Responsible Party)

Last Update Posted 2021-06-30

Study record dates





+

Patient

• 600 patients with dual-chamber CIEDs possessing AP Scan™ function

Inclusion


• 1) age \geq 19 years and 2) CHA₂DS₂VASc score \geq 1 in males or \geq 2 in females

Exclusion

• 1) CIED without atrial lead, 2) persistent or permanent AF or AFL, 3) history of catheter or surgical ablation of AF or AFL, 4) ≥moderate degree of valvular steno-insufficiency, 5) chronic obstructive pulmonary disease, 6) under current treatment for SDB, or 7) life expectancy <1 year



Study flow






Diagnostic parameters from device interrogation.


	Variables and values
AP scan	Patient sleep time, maximum and minimum RDI value, mean and median RDI, initial severity of sleep apnea, and number of days with RDI ≥30, 15 ≤ RDI <30, or RDI < 15
Atrial high rate episode	Total number of AHRE, total time in AHRE, percentage of time in AHRE, and number of episodes with duration <1 min, 1 min \leq duration <1 h, 1 h \leq duration <24 h, 24 h \leq duration <48 h, duration \geq 48 h
Ventricular high rate episode	Number of sustained episodes, date of first sustained episode, number and success of anti-tachycardia pacing or shock therapy
Lead integrity	Sensing amplitudes (mV), sensitivity (fixed or auto gain control, mV), impedance (ohm), pacing threshold (V at ms)

AHRE, atrial high rate episode; RDI, respiratory disturbance index.



RDI measurement








Details of follow-up outcomes.

	CIED-detected and clinical outcomes			
Primary outcomes				
Atrial arrhythmia	CIED-detected atrial high rate episode			
	Clinical atrial fibrillation or flutter			
Secondary outcomes				
AF-related outcomes	Thromboembolic events, de novo heart failure or			
	decompensation of chronic heart failure, AF progression to			
	persistent/permanent form, ablation therapy of AF			
MACE	Cardiac death, stroke, atrial fibrillation or flutter, ventricular			
Mantalita	tachyarrhythmia, and hospitalization for heart failure			
Mortality	Overall and cardiovascular mortality			
Ventricular arrhythmia	Clinical events and CIED-detected ventricular high rate			
	episodes, defibrillation therapy (shock or anti-tachycardia			
	pacing)			
At 1- and 2-year after CIED implantation				
Quality of life	Assessment by EuroQol five dimensions questionnaire			
Severity of SDB	Assessment by Berlin questionnaire			



Interim results





Baseline characteristic of total patient (n = 533)

Demographic data	Total patients n = 533	
Age (years)	68.4 ± 12.0	
Gender (male)	289 (54.2)	
Body mass index (kg/m2)	24.7 ± 3.2	
Hypertension	367 (68.9)	
Diabetes	171 (32.1)	
Heart failure	157 (29.5)	
LVEF < 40%	143 (28.4)	
LVEF (%)	52.6 ± 16.5	
GFR <60ml/min	226 (42.4)	
CHA ₂ DS ₂ VASc score	3.2 ± 1.5	
CrCl (ml/min)	67.7 ± 30.1	
ICD or CRT-D	215 (40.3)	





RDI values of total patients (n = 533)

SDB monitoring data	First 3 mons	Total follow-up
Average RDI	33.0 ± 11.1	32.9 ± 10.3
Median RDI	32.4 ± 11.7	32.3 ± 10.9
Maximal RDI	54.9 ± 16.3	64.5 ± 23.6
Minimal RDI	16.6 ± 9.6	12.0 ± 7.0
Max RDI ≥ 30	511 (95.9%)	530 (99.3%)




RDI report day









n = 533	First 3 mons	Total follow-up
Monitoring days	97.9 ± 7.3	654.7 ± 156.0
RDI report days	71.6 ± 31.5	472.0 ± 236.0
RDI report day/ monitoring day (%)	73.1 ± 31.5	72.4 ± 30.7



Summary

- The DEDiCATES study was designed to evaluate the relationships between devicedetected SDB and various cardiovascular outcomes in patients with CIEDs during 2-year follow-up.
- This study included largest patient number, and high-voltage defibrillating devices as well as pacemaker.
- SDB is very frequently detected in CIED patients. The optimal RDI-related parameter and its threshold to predict cardiovascular events are planned to be analyzed primarily.
- All device and clinical data collected during 2-year follow-up are being now adjudicated.



Acknowledgement

We thank all the participating centers for their DEDICATION to the DEDICATES study



Thank you for the attention

